Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) CFO Matt Abernethy sold 2,558 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.86, for a total transaction of $298,927.88. Following the transaction, the chief financial officer now owns 34,775 shares in the company, valued at $4,063,806.50. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Matt Abernethy also recently made the following trade(s):
- On Friday, January 31st, Matt Abernethy sold 1,283 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.87, for a total transaction of $196,132.21.
Neurocrine Biosciences Trading Down 1.4 %
Shares of NASDAQ NBIX traded down $1.56 during midday trading on Tuesday, reaching $113.47. The company had a trading volume of 312,694 shares, compared to its average volume of 1,314,670. The business's 50-day simple moving average is $137.55 and its 200 day simple moving average is $130.19. The stock has a market cap of $11.49 billion, a P/E ratio of 34.49 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. Analysts predict that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on NBIX. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price on the stock. HC Wainwright dropped their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Wedbush dropped their target price on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Bank of America lowered their price target on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $166.90.
Get Our Latest Research Report on NBIX
Institutional Trading of Neurocrine Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in NBIX. Cetera Investment Advisers increased its stake in shares of Neurocrine Biosciences by 7.9% in the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company's stock worth $979,000 after acquiring an additional 519 shares during the period. CWM LLC grew its position in Neurocrine Biosciences by 15.1% during the third quarter. CWM LLC now owns 7,884 shares of the company's stock valued at $908,000 after buying an additional 1,035 shares during the period. Exchange Traded Concepts LLC grew its position in Neurocrine Biosciences by 29.3% during the third quarter. Exchange Traded Concepts LLC now owns 7,964 shares of the company's stock valued at $918,000 after buying an additional 1,803 shares during the period. Creative Planning grew its position in Neurocrine Biosciences by 12.3% during the third quarter. Creative Planning now owns 12,999 shares of the company's stock valued at $1,498,000 after buying an additional 1,426 shares during the period. Finally, Vontobel Holding Ltd. grew its position in Neurocrine Biosciences by 12.7% during the third quarter. Vontobel Holding Ltd. now owns 14,590 shares of the company's stock valued at $1,681,000 after buying an additional 1,639 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
About Neurocrine Biosciences
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Read More
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
